Ergoloid mesylate
Ergoloid mesylate Uses, Dosage, Side Effects, Food Interaction and all others data.
Ergoloid Mesylate is an equiproportional preparation of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. All these components are produced by the fungus Claviceps purpurea and are all derivatives of the tetracyclic compound 6-methylergonovine. The derivatives of this fungus are identified to be about 350 different substances from which the components of the ergoloid mesylate mixture are composed of the dihydrogenated ergot alkaloid derivatives. The mixture of ergoloid mesylate was first developed by Novartis and FDA approved on November 5, 1953, but this specific formulation is now discontinued.Later in 1991, the mixture of ergoloid mesylates was retaken by Sun Pharmaceutical Industries and approved by the FDA. To know more about the individual components of the ergoloid mixture, please visit Epicriptine, Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
The mechanism of action of ergoloid mesylate is not completely established but it is thought that it increases both the blood flow and cerebral metabolism. Some studies have shown a significant improvement in alertness and memory, as well as a decline in confusion while some other benefits have shown a lack of effect. Its action produces a damper in the impulses from the vasomotor center which reduces the vascular tone which translates in the slow of pulse rate, prevention of compensatory tachycardia. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
| Trade Name | Ergoloid mesylate |
| Generic | Ergoloid mesylate |
| Ergoloid mesylate Other Names | co-dergocrine mesilate, co-dergocrine mesylate, co-dergocrine methanesulfonate, codergocrine mesilate, codergocrine mesylate, codergocrine methanesulfonate, Dihydroergotoxine Mesilate, Dihydroergotoxine Mesylate, Dihydroergotoxine Methanesulfonate, dihydroergotoxine methanesulfonates, dihydroergotoxine monomethanesulfonate, dihydrogenated ergot alkaloids, Ergoloid Mesilates, Ergoloid Mesylates, ergoloid methanesulfonate, ergoloid methanesulfonates, hydrogenated ergot alkaloids |
| Type | |
| Protein binding | Ergoloid mesylate presents a very large plasma protein binding that accounts for 81% of the administered dose. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Ergoloid mesylate is a nootropic with an unknown mechanism of action indicated in individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity.
It was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition as well as for age-related cognitive impairment. The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance. To know more about the individual components of the ergoloid mixture, please visit Dihydroergocristine and Dihydro-alpha-ergocryptine
Ergoloid mesylate is also used to associated treatment for these conditions: Mental activity decreased
How Ergoloid mesylate works
The general mechanism of action of ergoloid mesylate is the dual action of partial agonism/antagonism of adrenergic, dopaminergic and serotonergic receptors. The pharmacological activity is determined by the degree of activity of each component at the receptor site. To know more about the individual components of the ergoloid mixture, please visit Epicriptine, Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia. The excessive use of ergoloid mesylate can lead to ergotism. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
Food Interaction
- Take with or without food. Taking ergoloid mesylate with food may reduce gastrointestinal upset.
Volume of Distribution
The volume of distribution is about 2 L/kg. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine.
Elimination Route
The maximal plasma concentration of the components of the mixture of ergoloid mesylates is approximately 0.04 mcg/l. The analysis of the concentration of the major metabolites of each component indicates that all ergoloid mesylate are rapidly transformed after absorption. This finding is supported as they were found in one order of magnitude higher in concentration when compared to the original form. Ergoloid mesylate seems to have a very low absorption of only 25%. From this absorption by the GI tract, approximately 50% of the absorbed dose is eliminated by first-pass metabolism. After absorption, the maximal plasma concentration is attained after 3-4 hours and the oral bioavailability is very low. Simultaneous food ingestion has no effect on the extent of absorption but it does lower the absorption rate. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
Half Life
The reported plasma half-life of ergoloid mesylate is 3.5 hours while the terminal half-life is of 13 hours. To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine.
Clearance
To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine and Dihydroergocristine.
Elimination Route
The ergoloid mesylate mixture is mainly excreted via bile in feces. The ratio of the eliminated dose via urine after intravenous and oral administration is 8.4% and 2% respectively. Urinary excretion of the unchanged drug is very small and bile excretion is represented mainly by ergot metabolites conformed as conjugated compounds.[T191] To know more about the individual components of the ergoloid mixture, please visit Dihydro-alpha-ergocryptine, Dihydroergocornine and Dihydroergocristine.
Innovators Monograph
You find simplified version here Ergoloid mesylate
